Skip to content
✓ International Shipping Available

OMI® PGx Pharmacogenetics

Precision medicine for safer, more effective treatment

Contact Us Sample & Turnaround

Prescribing informed by your genetics

OMI® PGx Pharmacogenetics NGS Testing analyzes key genetic variants involved in drug metabolism, transport, and therapeutic response, helping your care team make more informed prescribing decisions.

Using advanced Next-Generation Sequencing (NGS) technology and internationally recognized pharmacogenetic guidelines, this analysis offers personalized insight into how your genetics may influence medication effectiveness and safety.

30%

30% of patients experience adverse drug reactions that could be prevented with PGx testing.

— PREPARE Randomized Clinical Trial (2023), The Lancet

Potential benefits

Identify medications that may be less effective for you Reduce the risk of adverse drug reactions Support safer medication selection Guide dose optimization Reduce trial-and-error prescribing

Who may benefit?

This assessment may be worth considering if you:

Have experienced medication side effects Require multiple prescription medications Have had limited success with previous treatments Are beginning long-term medication therapy Have a history of unusual drug responses Are seeking a more personalized approach to treatment

By understanding the genetic factors that influence drug response, your care team can make more informed therapeutic decisions tailored to you.

Clinical areas covered

Cardiovascular MedicineCardiovascular Medicine
Endocrine DisordersEndocrine Disorders
HypertensionHypertension
Respiratory MedicineRespiratory Medicine
DiabetesDiabetes
Neurology and PsychiatryNeurology & Psychiatry
InfectionsInfections
Urogenital ConditionsUrogenital Conditions
Digestive System DisordersDigestive System Disorders
Oncology Supportive CareOncology Supportive Care
GoutGout
Autoimmune DisordersAutoimmune Disorders
Musculoskeletal ConditionsMusculoskeletal Conditions
Commonly Prescribed MedicinesCommonly Prescribed Medicines

What is tested?

OMI® PGx NGS testing evaluates clinically relevant pharmacogenes involved in drug metabolism, transport, and therapeutic response.

3D molecular rendering of a protein, representing drug-metabolizing enzymesDrug-Metabolizing Enzymes
3D rendering of a protein embedded in a cell membrane, representing drug transportersDrug Transporters
3D rendering of a receptor protein spanning a membrane, representing drug targets and receptorsDrug Targets & Receptors

OMI® PGx utilizes high-depth Next-Generation Sequencing technology to help ensure accurate and reliable variant detection.

Analytical features

High-confidence sequencing depth (≥300×) Comprehensive pharmacogene coverage Automated variant annotation using established clinical databases Phenotype prediction models identifying metabolizer status Continuous interpretation updates aligned with evolving scientific evidence

What this means for patients

Personalized medication guidance

Patients may be classified into categories such as:

Poor Metabolizer
Intermediate Metabolizer
Normal Metabolizer
Rapid Metabolizer
Ultra-Rapid Metabolizer

Actionable clinical report

The final report integrates genetic findings with internationally recognized pharmacogenetic recommendations to provide practical guidance for your healthcare provider, including:

Identified pharmacogenetic variants Predicted metabolizer status Medication-specific gene interactions Potential efficacy considerations Adverse reaction risk assessments Dosing considerations where applicable Evidence-based therapeutic recommendations

Results you can trust

Interpretations are based on guidance from reputable sources, continuously reviewed and updated to reflect the latest pharmacogenetic evidence and CPIC guideline revisions.

CPIC PharmGKB FDA European Medicines Agency

This test can be performed using blood, a buccal swab, or saliva. Contact us for detailed sample collection guidance.

Results are typically available approximately 30 days from the date your sample reaches the lab.

International shipping is available for this test. Contact our team for guidance specific to your country.

Pirmohamed M, et al. "Preemptive pharmacogenomic testing for preventing adverse drug reactions: the PREPARE randomized clinical trial." The Lancet, 2023.

ISO ISO 15189 Accredited CAP CAP Accredited

Results from OMI® PGx Pharmacogenetics NGS Testing are not intended to be used as independent medical advice. Findings should be contextualized within the patient's broader clinical picture, and final treatment decisions rest with the patient and their treating physician. Always consult your physician regarding medication plans.

Not sure if this test is right for you?

Our team can help you decide whether OMI® PGx fits your treatment plan.

Contact Us